Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/9671
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Author: Branford, S.
Rudzki, Z.
Harper, A.
Grigg, A.
Taylor, K.
Durrant, S.
Arthur, C.
Browett, P.
Schwarer, A.
Ma, D.
Seymour, J.
Bradstock, K.
Joske, D.
Lynch, K.
Gathmann, I.
Hughes, T.
Citation: Leukemia, 2003; 17(12):2401-2409
Publisher: Nature Publishing Group
Issue Date: 2003
ISSN: 0887-6924
1476-5551
Abstract: We analyzed molecular responses in 55 newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients enrolled in a phase 3 study (the IRIS trial) comparing imatinib to interferon-alfa plus cytarabine (IFN+AraC). BCR-ABL/BCR% levels were measured by real-time quantitative RT-PCR and were significantly lower for the imatinib-treated patients at all time points up to 18 months, P<0.0001. The median levels for imatinib-treated patients continued to decrease and had not reached a plateau by 24 months. A total of 24 IFN+AraC-treated patients crossed over to imatinib. Once imatinib commenced, the median BCR-ABL/BCR% levels in these patients were not significantly different to those on first-line imatinib for the equivalent number of months. The incidence of progression in imatinib-treated patients, defined by hematologic, cytogenetic or quantitative PCR criteria, was significantly higher in the patients who failed to achieve a 1 log reduction by 3 months or a 2 log reduction by 6 months, P=0.002. A total of 49 patients were screened for BCR-ABL kinase domain mutations. Mutations were detected in two imatinib-treated patients who crossed over from IFN+AraC and both lost their imatinib response. In conclusion, first-line imatinib-treated patients had profound reductions in BCR-ABL/BCR%, which significantly exceeded those of IFN+AraC-treated patients and early measurements were predictive of subsequent response.
Keywords: BCR-ABL; imatinib; interferon alfa; quantitative PCR; BCR-ABL; mutation
Description: © 2009 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.
RMID: 0020031387
DOI: 10.1038/sj.leu.2403158
Published version: http://www.nature.com/leu/journal/v17/n12/abs/2403158a.html
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.